Skip to content

Fenebrutinib in PPMS: Insights from ACTRIMS Forum 2026

February 7, 2026 · 34 min

Show notes

Clinical trial results unveiled today at ACTRIMS Forum 2026 suggest that fenebrutinib may be a novel and effective treatment option for people living with primary progressive multiple sclerosis. In this exclusive episode providing the first expert discussion of the complete dataset, FENtrepid trial leads Prof. Amit Bar-Or (University of Pennsylvania) and Dr. Stephen Hauser (University of California San Francisco) break down what the fenebrutinib results really show. Together, they explore:

  • Why BTK inhibition is uniquely positioned to address progressive MS biology
  • How fenebrutinib compared to ocrelizumab in the Phase 3 FENtrepid PPMS trial
  • What the data suggest for patients with non-relapsing, chronic disease

Listen for a deep dive into the science and the clinical implications.

Editorial Note: At 21:49, the discussion refers to Müller cells. The correct term is Kupffer cells.

Download the transcript

--------------------------------

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

All episodes of The ECTRIMS Podcast

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.